PEN penumbrainc.com: Forward P/S Multiple

Graphic logo of Penumbra Corp (PEN)

The implementation of ESG standards and the greening of production create a foundation for growth, as confirmed by the expected price-to-sales ratio, where the current figure stands at 5.30. Neurosurgeons' confidence in the unique tools of Penumbra, Inc. (PEN) and the full capacity utilization of modernized catheter manufacturing plants ensure sustainable development. This indicator's trend helps assess the business value relative to its ability to generate future revenues.

penumbrainc.com - PEN Market Cap to Expected Sales Ratio (period 07/04/2022 - 11/14/2026)

Metric breakdowns and analytics for Penumbra Medical (PEN)

- current price and projected stock value:
Stock Price Penumbra|PEN - Average Forecast Price
- company stock capitalization data:
Market Capitalization Penumbra Medical|PEN - Business Value
- issuer book value statistics:
Book Value per Share Penumbra|PEN - Book Valuation of Business|Market Capitalization to Book Value Ratio penumbrainc.com|PEN - Cumulative Company Assets
- company total debt and liquidity indicators:
Total Debt to Capital Penumbra, Inc.|PEN - Long-Term Debt to Capital|Short-Term Debt to Equity Penumbra, Inc.|PEN - Company Debts|Debt to Book Value Penumbra Medical|PEN - Company Long-Term Loans and Borrowings|Company Short-Term Debts Penumbra|Quick Liquidity penumbrainc.com
- financial results and valuation multiples details:
PEN - Annual Net Income|Future Profit Penumbra, Inc.|PEN - P/E Multiple|Forward P/E Multiple Penumbra Corp|PEN - Growth-Adjusted Market Cap to Net Income|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Penumbra Medical|PEN - Profit before deduction of interest, taxes, depreciation and amortization|Earnings per share for the last twelve months Penumbra|PEN - Net earnings per share for the last 12 months|Quarterly EPS earnings growth penumbrainc.com|PEN - Earnings per share growth rate in current year|Net earnings per share growth forecast for next year Penumbra, Inc.
- sales volume and revenue indicators:
PEN - Company Sales Volume|Company Future Sales Volume Penumbra|PEN - Market Cap to Sales Volume|Price-to-Projected Revenue Ratio Penumbra Medical
Summary company analytics:Penumbra (PEN)
Product sample of Penumbra, Inc.

The stability of Penumbra, Inc. (PEN) is underpinned by Adam Elsesser's reputation and the systemic implementation of innovations in thrombectomy. This indicator compares the current market value of the stock with expected sales volume, allowing for a real-time assessment of the value of each unit of future revenue. Investors should analyze the forward price-to-sales ratio trend to verify business expansion rates between quarterly reports.

Key competitors

Forward P/S Multiple DXCM (Dexcom)|Novanta Inc (NOVT) - Market Cap to Future Revenue Ratio|Haemonetics Corp. - Forward P/S Multiple|INSP (Inspire Medical Systems Inc) - Market Cap to Projected Revenue|PRCT: Forward P/S Multiple|CNMD - Market Cap to Expected Sales Ratio|PLSE (Pulse Biosciences) - Forward P/S Multiple|Forward Price-to-Revenue Multiple InMode Ltd (INMD)|Forward P/S Multiple PMI|Forward P/S Multiple Surmodics Inc. (SRDX)|Price-to-Projected Revenue Ratio Senseonics Holdings SENS|neuropace.com - Price-to-Projected Revenue Ratio|TCMD: Forward Price-to-Revenue Multiple|Forward Price to Sales SNWV (SANUWAVE Health)|OM: Forward P/S Multiple|Market Cap to Future Revenue Ratio Electromed (ELMD)|Price-to-Projected Revenue Ratio LENSAR, Inc.|RCEL - Projected Price to Revenue|Forward Price-to-Revenue Multiple PROF (Profound Medical Corp.)|Forward P/S Multiple bairdmed.com (BDMD)|Forward P/S Multiple EDAP (EDAP TMS)|Market Cap to Expected Sales Ratio Apyx Medical Corp (APYX)|ICCM - Price-to-Projected Revenue Ratio|Future Price to Revenue LUNG|telabio.com (TELA) - Price-to-Projected Revenue Ratio|Forward Price-to-Revenue Multiple CytoSorbents Corporation|SRTS (Sensus Healthcare Corp) - Forward P/S Multiple|Market Cap to Future Revenue Ratio Zynex Corp ZYXI|Price-to-Projected Revenue Ratio electroCore, Inc. (ECOR)|vicarioussurgical.com - Market Cap to Projected Revenue|Inspira Technologies - Forward Price-to-Revenue Multiple|Price to Expected Revenue Ratio ICU (SeaStar Medical Holding Corporation)|IRIX - Price-to-Projected Revenue Ratio|Future Price to Revenue INBS|XAIR: Forward P/S Multiple|Market Cap to Future Revenue Ratio profusa.com (PFSA)|Price-to-Projected Revenue Ratio STRATA Skin Sciences Inc.|Market Cap to Projected Revenue GCTK (glucotrack.com)|Forward Price-to-Revenue Multiple NAOV (NanoVibronix)|Forward P/S Multiple Venus Concept Corporation (VERO)|Price-to-Projected Revenue Ratio Nuwellis, Inc. NUWE|AEMD - Forward Price-to-Revenue Multiple|TransEnterix - Forward P/S Multiple|AVGR: Price-to-Projected Revenue Ratio|BioSig Technologies, Inc (BSGM) - Price-to-Projected Revenue Ratio|Cutera Inc - Forward Price to Sales|KNW (Know Labs, Inc.) - Forward P/S Multiple|Forward P/S Multiple inarimedical.com|Forward Price-to-Revenue Multiple NVRO (Nevro)|RSLS (reshapelifesciences.com) - Forward Price to Sales|Forward P/S Multiple SILK (Silk Road Medical Inc.)